跳转至内容
Merck

SML0580

Sigma-Aldrich

Nutlin-3a

≥98% (HPLC)

别名:

(-)-Nutlin-3, 4 - [[(4S,5R)-4,5-二(4-氯苯基)-2-(2-异丙氧基-4-甲氧基苯基)-4,5-二氢咪唑-1-基]羰基]哌嗪-2-酮, 4 - [[(4S,5R)-4,5-二(4-氯苯基)-4,5-二氢-2- [4-甲氧基-2-(1-甲基乙氧基)苯基] -1H-咪唑-1-基]羰基] -2-哌嗪, Nutlin 3a, ( - ) - 4-(4,5-双(4-氯苯基)-2-(2-异丙氧基-4-甲氧基苯基)-4,5-二氢-1H-咪唑-1-羰基)哌嗪-2-酮

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C30H30Cl2N4O4
分子量:
581.49
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

ligand

nutlin-3a

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D -130 to -154° (c=0.5, CDCl3)

反應適用性

reagent type: ligand

顏色

white to beige

溶解度

DMSO: 5 mg/mL, clear

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

O=C(N1CC(NCC1)=O)N2[C@H](C3=CC=C(Cl)C=C3)[C@H](C4=CC=C(Cl)C=C4)N=C2C5=CC=C(OC)C=C5OC(C)C

InChI

1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13,16,18,27-28H,14-15,17H2,1-3H3,(H,33,37)/t27-,28+/m0/s1

InChI 密鑰

BDUHCSBCVGXTJM-WUFINQPMSA-N

應用

Nutlin-3a 已被用作肿瘤抑制因子 p53 (TP53) 稳定剂和小鼠双微体 2 同源物 (MDM2)-p53 相互作用的抑制剂。

生化/生理作用

Nutlin-3a [(-)-Nutlin] 是外消旋 MDM2 拮抗剂 Nutlin-3 的更有效非对映异构体。它被称为对映体 a,因为它将作为外消旋 nutlin-3 手性纯化的第一峰洗脱。Nutlin-3a 是 MDM2(小鼠双微体 2)与 p53 结合的强效抑制剂,可诱导 p53 调控基因的表达,并在表达功能性 p53 的细胞中显示出强效的抗增殖活性。Nutlin-3a 的效力是 Nutlin-3b 的 150 倍。
Nutlin-3a 是一种强效非遗传毒性药物。作为肿瘤抑制因子 p53 (TP53) 激活剂和稳定剂。

特點和優勢

这种化合物是细胞凋亡研究的特色产品。 点击此处 ,发现更多特色细胞凋亡产品。访问sigma.com/discover-bsm了解更多关于其他研究领域的生物活性小分子的信息。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Long non-coding RNA NEAT1-modulated abnormal lipolysis via ATGL drives hepatocellular carcinoma proliferation.
Liu X, et al.
Molecular Cancer, 17(1), 90-90 (2018)
Conservation and Divergence of p53 Oscillation Dynamics across Species.
Jacob S O, et al.
Cell Systems, 5(4), 410-417 (2017)
Manasi Das et al.
Nanomedicine : nanotechnology, biology, and medicine, 11(2), 379-389 (2014-09-23)
The promising proposition of multifunctional nanoparticles for cancer diagnostics and therapeutics has inspired the development of theranostic approach for improved cancer therapy. Moreover, active targeting of drug carrier to specific target site is crucial for providing efficient delivery of therapeutics
Joana Soares et al.
Molecular oncology, 11(6), 612-627 (2017-03-16)
The transcription factor p53 plays a crucial role in cancer development and dissemination, and thus, p53-targeted therapies are among the most encouraging anticancer strategies. In human cancers with wild-type (wt) p53, its inactivation by interaction with murine double minute (MDM)2
CITED2 affects leukemic cell survival by interfering with p53 activation.
Mattes K, et al.
Cell Death & Disease, 8(10), e3132-e3132 (2017)

商品

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

查看所有结果

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门